### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jindrich Cinatl et al.

Serial No.: 10/559,495

Filed: May 23, 2006

For: GLYCYRRHIZIN OR DERIVATIVES

THEREOF FOR TREATING OR PREVENTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: SONN:086US

Confirmation No.: 8717

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: February 7, 2007

### INFORMATION DISCLOSURE STATEMENT

#### MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to

be an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/SONN:086US.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Mark B. Wilson

Reg. No. 37,259

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

February 7, 2007

Form PTO-1449 (modified)  List of Patents and Publications for Applicant's		Atty. Docket No. Serial No. SONN:086US 10/559,495	
		Applicant Jindrich Cinatl et al.	
INFORMATION DISCLOSURE S	TATEMENT		
(Use several sheets if necessary)		Filing Date: May 23, 2006	Group: 1614
U.S. Patent Documents	Foreign Patent Documents		Other Art
See Page 1	S	See Page 1	See Page 1-2

### **U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,019,495	05/28/91	Shanbrom	435	1.1	11/07/89

## **Foreign Patent Documents**

Exam. Init.	1 I		1.5.1			Language		
	Bi	EP 0312222	04/19/89	Europe	English			
	B2	EP 0518533	12/16/92	Europe	English			
	В3	JP 04-128237	04/28/92	Japan	Japanese (English Abstract)			
	B4	RU 2024542	12/15/94	Russia	Russian			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Ref. Init. Des.		Citation				
	CI	Baltina et al., "Transformation of Glygyrrhizic Acid. VII. Synthesis of Triterpene Glycopeptides Containing Alkyl Esters of L-Amino Acids," Chemistry of Natural Compounds, 30:238-244, 1994.				
	C2	Baltina et al., "Transformations of Glycyrrhizic Acid. X. Synthesis of New Esters," Russian Journal of Org. Chem., 30:1705-1711, 1994.				
	C3	Baltina et al., "Transformations of Glycyrrhizic Acid VIII. Synthesis of Immunomodulating Glycopeptides Using tert-Butyl Esters of Amino Acids," Russian J. Bioorg. Chem., 20:778-784, 1994.				
	C4	Baltina, "Chemical Modification of Glycyrrhizic Acid As A Route to New Bioactive Compounds for Medicine," Current Medicinal Chemistry, 10:155-171, 2003.				
	C5	Briolant et al., "In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: Synergistic effect of interferon-alpha and ribavirin combination," Antiviral Research, 61: 111-117, 2004.				
	C6	Cinatl et al., "Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus," <i>Lancet</i> , 361:2045-2046, 2003.				

25718160.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. SONN:086US	Serial No. 10/559,495	
List of Patents and Publications for	Applicant's	Applicant Jindrich Cinatl et al.	(	
INFORMATION DISCLOSURE STATEMENT				
(Use several sheets if necessa	ry)	Filing Date: May 23, 2006	Group: 1614	
U.S. Patent Documents	Foreign	Patent Documents	Other Art	
See Page 1	1 3	See Page 1	See Page 1-2	

# Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Crance et al., "Interferon, ribavirin, 6-azauridine and glycyrrhizin: Antiviral compounds active against pathogenic flaviviruses," Antiviral Research, 58:73-79, 2003.
	C8	Database Caplus, Database Accession no. 1995;863060.
	C9	Database Caplus, Database accession no. 1995:892869.
	C10	Drosten et al., "Identification of a Novel Coronavirus in Patients with Severe Acuts Respiratory Syndrome," New Engl. J. Med., 348:1967-1976, 2003.
	C11	Jeong and Kim, "Induction of inducibile nitric oxide synthase expression by 18beta- glycyrrhetinic acid in macrophages," FEBS Lett., 513:208-212, 2002.
	C12	Kondratenko et al., "Synthesis and Immunostimulating Activity of Cysteine-Containing Derivatives of Glycyrrhizic Acid," Russian J. Bioorg. Chem., 30:53-59, 2004.
	C13	Kondratenko et al., "The Synthesis and Antiviral Activity of Glycyrrhizic Acid Conjugates with alpha-D-Glucosamine and Some Glycosylamines," Russian J. Bioorg. Chem., 30:275-282, 2004.
	C14	Perlman, "Pathogenesis of Coronavirus-Induced Infections: Revies of Pathological and Immunological Aspects," Adv. Exp. Med. Biol., 440-503-513, 1998.
	C15	Utsunomiya et al., "Glycyrrhizin, an Active Component of Licorice Roots, Reduces Morbidity and Mortality of Mice Infected with Lethal Doses of Influenza Virus," Antimicrobial Agents and Chemotherapy, 41:551-556, 1996.

25718160.1

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.